2. Signaling Pathways
  3. Anti-infection
  4. RSV

RSV

Respiratory syncytial virus

RSV

Related Products

PDF 0.17 MB

RSV (Respiratory syncytial virus) is a leading cause of acute respiratory infections. RSV can exploit host immunity and cause a strong inflammatory response that leads to lung damage and virus dissemination. There is a single RSV serotype with two major antigenic subgroups, A and B.

RSV is a non-segmented negative-sense single-stranded enveloped RNA virus that belongs to the family of Paramyxoviridae, genus Pneumovirus, subfamily Pneumovirinae. Its 10 genes encode 11 proteins since two overlapping open reading frames in the M2 mRNA yield two distinct matrix proteins, M2-1 and M2-2. The viral envelope contains three proteins, the G glycoprotein, the fusion (F) glycoprotein, and the small hydrophobic (SH) protein. The RSV virus comprises five other structural proteins, the large (L) protein, nucleocapsid (N), phosphoprotein (P), matrix (M), and M2-1, and two non-structural proteins (NS1 and NS2).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0434
    Ribavirin
    		Inhibitor 99.96%
    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.
    Ribavirin
  • HY-15455
    Roflumilast
    		Inhibitor 99.98%
    Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast
  • HY-104032
    Ac-CoA Synthase Inhibitor1
    		Inhibitor 99.33%
    Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 µM. Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV).
    Ac-CoA Synthase Inhibitor1
  • HY-P9944
    Palivizumab
    		Inhibitor 99.43%
    Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice.
    Palivizumab
  • HY-N0662
    Amentoflavone
    		Inhibitor 99.81%
    Amentoflavone (Didemethyl-ginkgetin) is a potent and orally active GABA(A) negative modulator. Amentoflavone also shows anti-inflammatory, antioxidative, anti-viral, anti-tumor, anti-radiation, anti-fungal, antibacterial activity. Amentoflavone induces apoptosis and cell cycle arrest at sub-G1 phase.
    Amentoflavone
  • HY-N0662R
    Amentoflavone (Standard)
    		Inhibitor
    Amentoflavone (Standard) is the analytical standard of Amentoflavone. This product is intended for research and analytical applications. Amentoflavone (Didemethyl-ginkgetin) is a potent and orally active GABA(A) negative modulator. Amentoflavone also shows anti-inflammatory, antioxidative, anti-viral, anti-tumor, anti-radiation, anti-fungal, antibacterial activity. Amentoflavone induces apoptosis and cell cycle arrest at sub-G1 phase.
    Amentoflavone (Standard)
  • HY-161877
    GS-7682
    		Inhibitor
    GS-7682 is an antiviral compound. GS-7682 has inhibitory activity against pneumoviruses and picornaviruses. GS-7682 can be used in the study of respiratory diseases such as asthma and chronic obstructive pulmonary disease.
    GS-7682
  • HY-169313
    HRSV/HMPV-IN-1
    		Inhibitor
    HRSV/HMPV-IN-1 (compound 3) is a HRSV/HMPV inhibitor with the EC50 values of ＜ 0.2 μM and ＜ 0.5 μM for human RSV-A and human MPV A2 TN/94-49, respectively. HRSV/HMPV-IN-1 can be used for study of bronchiolitis and pneumonia.
    HRSV/HMPV-IN-1
  • HY-109142
    Ziresovir
    		Inhibitor
    Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species.
    Ziresovir
  • HY-126303C
    GS-443902 trisodium
    		Inhibitor 99.98%
    GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).
    GS-443902 trisodium
  • HY-P99756
    Nirsevimab
    		Inhibitor
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.
    Nirsevimab
  • HY-146246
    EIDD-2749
    		Inhibitor 99.85%
    EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
    EIDD-2749
  • HY-12983
    ALS-8112
    		Inhibitor 98.90%
    ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
    ALS-8112
  • HY-12283
    Rostafuroxin
    		Inhibitor 99.03%
    Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity.
    Rostafuroxin
  • HY-P99209
    Motavizumab
    		98.35%
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
    Motavizumab
  • HY-N6771
    Cyclopiazonic acid
    		Inhibitor 99.69%
    Cyclopiazonic acid is an endoplasmic reticulum calcium ATPase (ECAs) inhibitor and human respiratory syncytial virus (RSV) inhibitor (EC50 value of 4.13 μ M), which can reduce the antagonistic effect of 5-HT receptors in rat thoracic aorta, induce p53 dependent cell apoptosis and reproductive toxicity in mouse testes, and inhibit the biological activation of aflatoxin B[1][4][5].
    Cyclopiazonic acid
  • HY-112180
    Rilematovir
    		Inhibitor ≥98.0%
    Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
    Rilematovir
  • HY-16727
    Presatovir
    		Inhibitor 99.91%
    Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC50 value of 0.43 nM.
    Presatovir
  • HY-123475
    Sisunatovir
    		Inhibitor 99.40%
    Sisunatovir (RV521), an orally available inhibitor of the RSV protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
    Sisunatovir
  • HY-11097
    TMC353121
    		Inhibitor ≥98.0%
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
    TMC353121
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity